Skip to main content
SpringerLink
Log in

Dysthyroid optic neuropathy: evaluation and management

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background

Dysthyroid optic neuropathy (DON) is a serious complication of Graves orbitopathy (GO) from optic nerve dysfunction that may result in permanent loss of vision.

Purpose

This paper reviews the current knowledge of DON, including its pathogenesis and epidemiology, clinical and radiologic features, and management choices and outcomes.

Methods

Literature review and author retrospective case series.

Results

Over 90% of DON cases are related to nerve compression by enlarged extraocular muscles (EOM) while the remainder are caused by stretching of the optic nerve without compression. DON’s incidence is 5–8% of GO cases. Risk factors include advancing age, male gender, smoking and diabetes mellitus, and these cases should be referred promptly to an ophthalmologist or GO clinic to rule out DON and for ongoing care. Clinical features of DON may include reduction in central and colour vision (unexplained by other ocular disorders), afferent pupil defect and/or optic disc edema. Since most cases are associated with enlarged EOM, restricted motility and soft tissue venous congestion are common. Visual fields and optical coherence tomography (OCT) help confirm the diagnosis while CT or MRI Scans show apical optic nerve compression or proptosis with optic nerve stretch. Standard therapy includes iv/oral corticosteroids (CS) with partial response in most cases, but often relapse with tapering. Radiotherapy may delay or avoid surgery and may prevent the onset of DON when combined with CS in high-risk individuals. The benefits of newer biologic targeted therapy are not clear. Orbital decompression surgery often has positive outcomes, even in cases of severe vision loss or delayed surgery. The most common surgical complication is worsening strabismus, which may worsen visual function and quality of life. In rare cases, permanent vision loss from DON may occur despite full therapy.

Conclusions

Although DON may cause vision loss, most cases are reversible if recognized and managed in a timely manner.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. McKeag D, Lane CM, Lazarus JH et al (2007) Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy survey. Br J Ophthalmol 91:455–458

    PubMed  Google Scholar 

  2. Dolman PJ (2012) Evaluating graves orbitopathy. Best Pract Res Clin Endocrinol Metab 26(3):229–248

    PubMed  Google Scholar 

  3. Saeed P, Tavakoli Rad S, Bisschop PHLT (2018) Dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg 34(4 Suppl 1):S60–S67

    PubMed  Google Scholar 

  4. Blandford AD, Zhang D, Chundury RV, Perry JD (2017) Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol 12(2):111–121

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Bahn RS (2015) Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47(10):773–778

    CAS  PubMed  Google Scholar 

  6. Smith TJ (2020) Teprotumumab in thyroid-associated ophthalmopathy: rationale for therapeutic insulin-like growth factor-I receptor inhibition. J Neuroophthalmol 40(1):74–78

    PubMed  Google Scholar 

  7. Dolman PJ (2018) Grading severity and activity in thyroid eye disease. Ophthal Plast Reconstr Surg 34(4S):S34–S40

    PubMed  Google Scholar 

  8. Davies MJ, Dolman PJ (2016) Levator muscle enlargement in thyroid eye disease-related upper eyelid retraction. Ophthalmic Plast Reconstr Surg 33(1):35–39

    Google Scholar 

  9. Dolman PJ, Rootman J (2005) Predictors of disease severity in thyroid-related orbitopathy. (chap18) Orbital Disease. Present status and future challenges. Taylor and Francis

  10. Rundle FF (1960) Ocular changes in Graves’ disease. QJM 29:113–126

    PubMed  Google Scholar 

  11. Bartalena L et al (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285

    CAS  PubMed  Google Scholar 

  12. Mourits MP, Prummel MF, Wiersinga WM et al (1997) Clinical activity score as a guide in the management of patients with Graves’ Ophthalmopathy. Clin Endocrinol 47:9

    CAS  Google Scholar 

  13. Dolman PJ, Rootman J (2006) VISA classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg 22(5):319–324

    PubMed  Google Scholar 

  14. Day RM, Carroll FD (1967) Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction. Trans Am Ophth Soc 65:41–51

    CAS  Google Scholar 

  15. Kennerdell JS, Rosenbaum AE, El-Hoshy MH (1981) Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography. Arch Ophthalmol 99(5):807–809

    CAS  PubMed  Google Scholar 

  16. Kazim M, Trokel SL, Acaroglu G, Elliott A (2000) Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br J Ophthalmol 84(6):600–605

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Rose GE, Vahdani K (2020) Optic nerve stretch is unlikely to be a significant causative factor in dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg 36(2):157–163

    PubMed  Google Scholar 

  18. Wong Y, Dickinson J, Perros P et al (2018) A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom. Eye 32(10):1555–1562

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Dolman PJ (2019) Dysthyroid optic neuropathy: evaluation and management. Hong Leong Professorship Special Lecture. IGOS 4th International Symposium, Singapore

  20. Khong JJ, Finch S, De Silva C et al (2016) Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. J Clin Endocrinol Metab 1010(7):2711–2720

    Google Scholar 

  21. Kalmann R, Mourits MP (1999) Diabetes mellitus: a risk factor in patients with Graves' orbitopathy. Br J Ophthalmol 83(4):463–465

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Shams PN, Ma R, Pickles T, Rootman J (2014) Dolman PJ Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 157(6):1299–1305

    PubMed  Google Scholar 

  23. Dickinson AJ, Hintschich C (2017) In: Wiersinga WM, Kahaly GJ (eds) Graves’ orbitopathy: a multidisciplinary approach—questions and answers. Karger, Basel, pp 19–20

    Google Scholar 

  24. Weis E, Heran MK, Jhamb A, Chan AK, Chiu JP, Hurley MC, Rootman J (2011) Clinical and soft-tissue computed tomographic predictors of dysthyroid optic neuropathy: refinement of the constellation of findings at presentation. Arch Ophthalmol 29(10):1332–1336

    Google Scholar 

  25. Choi CJ, Oropesa S, Callahan AB, Glass LR et al (2017) Patterns of visual field changes in thyroid eye disease. Orbit 36(4):201–207

    PubMed  Google Scholar 

  26. Lao TW, Rong SS, Ling AN, Brelén ME et al (2019) Electrophysiological studies in thyroid associated orbitopathy: a systematic review. Curr Opin Neurol 32(1):115–123

    Google Scholar 

  27. Micieli JA, Newman NJ, Biousse V (2017) The role of optical coherence tomography in the evaluation of compressive optic neuropathies. Expert Rev Ophthalmol 12(2):111–121

    Google Scholar 

  28. Giaconi JA, Kazim M, Rho T et al (2002) CT scan evidence of dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg 18(3):177–182

    PubMed  Google Scholar 

  29. Oropesa S, Dunbar KE, Godfrey KJ, Callahan AB, Campbell AA, Kazim M (2018) Predominant contribution of superior rectus-levator complex enlargement to optic neuropathy and inferior visual field defects in thyroid eye disease. Ophthalmic Plast Reconstr Surg 35:262–265

    Google Scholar 

  30. Callahan AB, Campbell AA, Oropesa S et al (2018) The Columbia thyroid eye disease-compressive optic neuropathy diagnostic formula. Ophthalmic Plast Reconstr Surg 34(4 Suppl 1):S68–S71

    PubMed  Google Scholar 

  31. Zhao LQ, Yu DY, Cheng JW (2019) Intravenous glucocorticoids therapy in the treatment of Graves’ ophthalmopathy: a systematic review and meta-analysis. Int J Ophthalmol 12(7):1177–1186

    PubMed  PubMed Central  Google Scholar 

  32. Bartalena L, Krassas GE, Wiersinga W, Marcocci C et al (2012) (2012) European Group on Graves’ Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab 97(12):4454–4463

    CAS  PubMed  Google Scholar 

  33. Dolman PJ, Rath S (2012) Orbital radiotherapy for thyroid eye disease. Curr Opin Ophthalmol 23(5):427–432

    PubMed  Google Scholar 

  34. Gold KG, Scofield S, Isaacson SR, Stewart MW, Kazim M (2018) Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy. Ophthalmic Plast Reconstr Surg 34(2):172–177

    PubMed  Google Scholar 

  35. Salvi M, Vannucchi G, Curro N et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate-severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100:402–431

    Google Scholar 

  36. Stan MN, Garrity JA, Carranza Leon BG, Prabin T et al (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100(2):432–441

    CAS  PubMed  Google Scholar 

  37. Bartalena L, Baldeschi L, Boboridis K, Eckstein A et al (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of graves' orbitopathy. Eur Thyroid J 5:9–26

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Khanna D, Chong KK, Afifiyan NF, Hwang CJ et al (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117(1):133–139

    PubMed  Google Scholar 

  39. Perez-Moreiras JV et al (2018) Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181–190

    CAS  PubMed  Google Scholar 

  40. Douglas RS, Kahaly GJ, Patel A, Sile S et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341–352

    CAS  Google Scholar 

  41. Tooley AA, Godfrey KJ, Kazim M (2019) Evolution of thyroid eye disease decompression-dysthyroid optic neuropathy. Eye (Lond) 33(2):206–211

    Google Scholar 

  42. Jefferis JM, Jones RK, Currie ZI, Tan JH, Salvi SM (2018) Orbital decompression for thyroid eye disease: methods, outcomes, and complications. Eye 32:626–636

    CAS  PubMed  Google Scholar 

  43. Choe CH, Cho R, Elner VM (2011) Comparison of lateral and medial orbital decompression for the treatment of compressive optic neuropathy in thyroid eye disease. Ophthalmic Plast Reconstr Surg 27(1):4–11

    PubMed  Google Scholar 

  44. Boboridis KG, Bunce C (2011) Surgical orbital decompression for thyroid eye disease. Cochrane Database Syst Rev. 12:CD007630

    Google Scholar 

  45. Chu EA, Miller NR, Lane AP (2009) Selective endoscopic decompression of the orbital apex for dysthyroid optic neuropathy. Laryngoscope 119(6):1236–1240

    PubMed  Google Scholar 

  46. Liao SL, Chang TC, Lin LL (2006) Transcaruncular orbital decompression: an alternate procedure for Graves ophthalmopathy with compressive optic neuropathy. Am J Ophthalmol 141(5):810–818

    PubMed  Google Scholar 

  47. Jeon C, Shin JH, Woo KI, Kim YD (2012) Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy. Korean J Ophthalmol 26(2):73–79

    PubMed  PubMed Central  Google Scholar 

  48. Badilla J, Dolman PJ (2008) Intracranial hemorrhage complicating an orbital decompression. Orbit 27(2):143–145

    PubMed  Google Scholar 

  49. Badilla J, Dolman PJ (2007) Cerebrospinal fluid leaks complicating orbital or oculoplastic surgery. Arch Ophthalmol 125(12):1631–1634

    PubMed  Google Scholar 

  50. Fayers T, Dolman PJ (2011) Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol 95(12):1670–1674

    PubMed  Google Scholar 

  51. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM (1998) Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol 82(7):773–779

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Fayers T, Fayers PM, Dolman PJ (2016) Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease. Orbit 35(6):328–333

    PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada

    P. J. Dolman

Authors
  1. P. J. Dolman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. Dolman.

Ethics declarations

Conflict of interest

The author confirms there are no conflicts of interest.

Ethics approval

Not required for review article.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolman, P.J. Dysthyroid optic neuropathy: evaluation and management. J Endocrinol Invest 44, 421–429 (2021). https://doi.org/10.1007/s40618-020-01361-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-020-01361-y

Keywords

Search

Navigation